Sun Pharma’s big US bet is paying off. After spending over INR 4,688 crore to buy Concert Pharma, the company secured rights to Leqselvi for hair growth in alopecia areata patients. The drug has now received US FDA approval, but insiders say the real contest with global giants like Pfizer and Eli Lilly is only beginning.
Sun Pharmaceutical has won a trademark dispute in Bombay High Court, which barred Meghmani Lifesciences from using the drug mark “Esiraft.” The court accepted Sun’s claim that Meghmani’s “Esiraft” is visually and phonetically similar to Sun’s “Raciraft,” creating a strong likelihood of consumer confusion and amounting to infringement and passing off.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Sun Pharmaceutical has made a bold $13 billion bid for US firm Organon & Co., signaling its biggest push to shift from generics toward branded and innovative medicines. Sun is competing with other bidders for Organon, and a successful deal would effectively merge Organon into Sun Pharma, reshaping its global ambitions.
The Bombay High Court has barred a Navi Mumbai drugmaker from using the brand names “Absun” and “Absun Pharma,” siding with Sun Pharmaceutical Industries. In a long-running trademark dispute, the court ruled the competing names are deceptively similar to Sun Pharma’s established marks, potentially confusing consumers. The verdict effectively ends the decade-long legal battle.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
